OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Hanieh Mojtahedi, Niloufar Yazdanpanah, Nima Rezaei
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 51
Hanieh Mojtahedi, Niloufar Yazdanpanah, Nima Rezaei
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 51
Showing 26-50 of 51 citing articles:
Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia
Hana Komic, Malin S. Nilsson, Lovisa Wennström, et al.
Haematologica (2024)
Open Access | Times Cited: 1
Hana Komic, Malin S. Nilsson, Lovisa Wennström, et al.
Haematologica (2024)
Open Access | Times Cited: 1
Novel targeted therapies in chronic myeloid leukemia
Muhammad Sameer Ashaq, Qian Zhou, Zhuoran Li, et al.
Pharmaceutical Science Advances (2024) Vol. 2, pp. 100052-100052
Open Access | Times Cited: 1
Muhammad Sameer Ashaq, Qian Zhou, Zhuoran Li, et al.
Pharmaceutical Science Advances (2024) Vol. 2, pp. 100052-100052
Open Access | Times Cited: 1
Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies
Jie Sun, Liang Lou, Chengjun Zhu, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 1
Jie Sun, Liang Lou, Chengjun Zhu, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 1
Kinase-independent role of mTOR and on-/off-target effects of an mTOR kinase inhibitor
Cuiqing Fan, Mark Wunderlich, Xiongwei Cai, et al.
Leukemia (2023) Vol. 37, Iss. 10, pp. 2073-2081
Closed Access | Times Cited: 3
Cuiqing Fan, Mark Wunderlich, Xiongwei Cai, et al.
Leukemia (2023) Vol. 37, Iss. 10, pp. 2073-2081
Closed Access | Times Cited: 3
Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia
Han Han, Chen Zhao, Mengchen Liu, et al.
Biochemical Pharmacology (2023) Vol. 218, pp. 115875-115875
Closed Access | Times Cited: 3
Han Han, Chen Zhao, Mengchen Liu, et al.
Biochemical Pharmacology (2023) Vol. 218, pp. 115875-115875
Closed Access | Times Cited: 3
NK3.3-Derived Extracellular Vesicles Penetrate and Selectively Kill Treatment-Resistant Tumor Cells
A McCune, Jacki Kornbluth
Cancers (2023) Vol. 16, Iss. 1, pp. 90-90
Open Access | Times Cited: 3
A McCune, Jacki Kornbluth
Cancers (2023) Vol. 16, Iss. 1, pp. 90-90
Open Access | Times Cited: 3
Novel Dicarboximide BK124.1 Breaks Multidrug Resistance and Shows Anticancer Efficacy in Chronic Myeloid Leukemia Preclinical Models and Patients’ CD34+/CD38− Leukemia Stem Cells
Iga Stukan, Marek Gryzik, Grażyna Hoser, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3641-3641
Open Access | Times Cited: 4
Iga Stukan, Marek Gryzik, Grażyna Hoser, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3641-3641
Open Access | Times Cited: 4
Understanding the interaction between leukaemia stem cells and their microenvironment to improve therapeutic approaches
Leandro Marcelo Martinez, Mónica L. Guzmán
British Journal of Pharmacology (2023) Vol. 181, Iss. 2, pp. 273-282
Closed Access | Times Cited: 2
Leandro Marcelo Martinez, Mónica L. Guzmán
British Journal of Pharmacology (2023) Vol. 181, Iss. 2, pp. 273-282
Closed Access | Times Cited: 2
MicroRNA based combinatorial therapy against TKIs resistant CML by inactivating the PI3K/Akt/mTOR pathway: a review
Priyanka Singh
Medical Oncology (2023) Vol. 40, Iss. 10
Closed Access | Times Cited: 2
Priyanka Singh
Medical Oncology (2023) Vol. 40, Iss. 10
Closed Access | Times Cited: 2
Exploration of treatment‐free remission in CML , based on molecular monitoring
Zhao Zhang, Wuneng Zhou, Xin Zhou, et al.
Cancer Medicine (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Zhao Zhang, Wuneng Zhou, Xin Zhou, et al.
Cancer Medicine (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 2
The role of miRNA- 96 and miRNA-150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients
Kawthar Ali Radhi, Bassam Francis Matti, Israa Hussein Hamzah
Human Gene (2023) Vol. 36, pp. 201166-201166
Closed Access | Times Cited: 1
Kawthar Ali Radhi, Bassam Francis Matti, Israa Hussein Hamzah
Human Gene (2023) Vol. 36, pp. 201166-201166
Closed Access | Times Cited: 1
Tackling Imatinib Resistance via Au‐nanoconjugates using A Cml Resistant Cell Line
Bilal Abdulmawjood, Catarina Roma‐Rodrigues, Pedro V. Baptista, et al.
Particle & Particle Systems Characterization (2023)
Closed Access | Times Cited: 1
Bilal Abdulmawjood, Catarina Roma‐Rodrigues, Pedro V. Baptista, et al.
Particle & Particle Systems Characterization (2023)
Closed Access | Times Cited: 1
State-transition Modeling of Blood Transcriptome Predicts Disease Evolution and Treatment Response in Chronic Myeloid Leukemia
David Frankhouser, Russell C. Rockne, Lisa Uechi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
David Frankhouser, Russell C. Rockne, Lisa Uechi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Decoding the Mystery of Blood Cancer: Cause, Diagnosis, and Management
Raja Sharma, Satendra Kumar, Niranjan Kaushik, et al.
Current Cancer Therapy Reviews (2024) Vol. 21, Iss. 1, pp. 40-53
Closed Access
Raja Sharma, Satendra Kumar, Niranjan Kaushik, et al.
Current Cancer Therapy Reviews (2024) Vol. 21, Iss. 1, pp. 40-53
Closed Access
Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid Leukemia through Advanced Non-Invasive Apoptosis Detection Sensor Version 2 Detection
Chia‐Hwa Lee, Kai‐Wen Hsu, Yao‐Yu Hsieh, et al.
Cells (2024) Vol. 13, Iss. 7, pp. 616-616
Open Access
Chia‐Hwa Lee, Kai‐Wen Hsu, Yao‐Yu Hsieh, et al.
Cells (2024) Vol. 13, Iss. 7, pp. 616-616
Open Access
Integrated functional genomic screening to bypass TKI resistance in chronic myeloid leukemia
Tumas Beinortas, Brian J.P. Huntly
Cell Reports Medicine (2024) Vol. 5, Iss. 5, pp. 101565-101565
Open Access
Tumas Beinortas, Brian J.P. Huntly
Cell Reports Medicine (2024) Vol. 5, Iss. 5, pp. 101565-101565
Open Access
Upregulation of miR-155 induces cell cycle arrest and apoptosis in chronic myeloid leukemia
Mahdi Edalati, Shaban Alizadeh, Asghar Abdoli, et al.
Sālnāmah va āmār. (2024) Vol. 31, Iss. 1, pp. 79-90
Closed Access
Mahdi Edalati, Shaban Alizadeh, Asghar Abdoli, et al.
Sālnāmah va āmār. (2024) Vol. 31, Iss. 1, pp. 79-90
Closed Access
Architecting lymphoma fusion: PROMETHEE-II guided optimization of combination therapeutic synergy
Syed Anas Ansar, Swati Arya, Nupur Soni, et al.
International Journal of Information Technology (2024)
Closed Access
Syed Anas Ansar, Swati Arya, Nupur Soni, et al.
International Journal of Information Technology (2024)
Closed Access
Chronic myeloid leukemia: where do we stand, where can we go?
Krzysztof Lewandowski, Jakub Lewandowski
Acta Haematologica Polonica (2022) Vol. 53, Iss. 3, pp. 153-165
Open Access | Times Cited: 2
Krzysztof Lewandowski, Jakub Lewandowski
Acta Haematologica Polonica (2022) Vol. 53, Iss. 3, pp. 153-165
Open Access | Times Cited: 2
Epidemiology of Chronic Myeloid Leukemia in Tunisia
Samia Menif
(2022) Vol. 17, Iss. 2, pp. 167-170
Open Access | Times Cited: 2
Samia Menif
(2022) Vol. 17, Iss. 2, pp. 167-170
Open Access | Times Cited: 2
Integrated Chemical Characterization, Network Pharmacology and Transcriptomics to Explore the Mechanism of Sesquiterpenoids Isolated from Gynura divaricata (L.) DC. against Chronic Myelogenous Leukemia
Xinyuan Ye, Long Wang, Xin Yang, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1435-1435
Open Access | Times Cited: 1
Xinyuan Ye, Long Wang, Xin Yang, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1435-1435
Open Access | Times Cited: 1
Discrimination of the chemotherapy resistance status of human leukemia and glioblastoma cell lines by MALDI-TOF-MS profiling
Martín Ledesma, Daniela Poodts, Sofía Amoia, et al.
Research Square (Research Square) (2023)
Open Access
Martín Ledesma, Daniela Poodts, Sofía Amoia, et al.
Research Square (Research Square) (2023)
Open Access
Advances in the Treatment of Chronic Myeloid Leukemia
Romeo-Gabriel Mihăilă
Recent Patents on Anti-Cancer Drug Discovery (2023) Vol. 19, Iss. 1, pp. 1-17
Closed Access
Romeo-Gabriel Mihăilă
Recent Patents on Anti-Cancer Drug Discovery (2023) Vol. 19, Iss. 1, pp. 1-17
Closed Access
Discrimination of the chemotherapy resistance status of human leukemia and glioblastoma cell lines by MALDI-TOF-MS profiling
Martín Ledesma, Daniela Poodts, Sofía Amoia, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access
Martín Ledesma, Daniela Poodts, Sofía Amoia, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access
Modulation of Autophagy and Apoptosis in Leukemia
Laura Della Torre, Antonio Beato, Vincenza Capone, et al.
Elsevier eBooks (2023), pp. 465-483
Closed Access
Laura Della Torre, Antonio Beato, Vincenza Capone, et al.
Elsevier eBooks (2023), pp. 465-483
Closed Access
